Bruker Mass Spec Wrap-Up: Last Chance at a Great QTOF Deal; New YouTube...
Before we forget, March is the last chance for our EU and US customers to get a great deal on a refurbished, warrantied, state-of-the-art Bruker maXis plus UHR-QTOF. This deal delivers a...
View ArticleClik here to view.
Quantitative and Qualitative Strategies for Targeted and Non-Targeted...
Targeted and Non-Targeted Metabolomics – Difficult to Strategize? Developing specific strategies for both targeted metabolomics studies can be challenging. And non-targeted studies? Historically, it’s...
View ArticleClik here to view.
US-HUPO 2014 – Bruker Heads to Seattle
If you’ll be attending the 10th Annual US HUPO Conference, (April 6-9, 2014, Seattle Westin Hotel), it promises to be a great show. This year, the focus is on advancing biology through technology and...
View ArticleClik here to view.
Metabolomics: NMR Marries Mass Spec…and Non-Targeted Metabolomics Researchers...
Two weeks ago, we posted a piece on complementary proteomics. It should come as no surprise that complementary approaches also apply to metabolomics (and even Food Safety & Testing). With...
View ArticleClik here to view.
“Hey, Sugar Sugar” – Glycomics Unravels Mysteries of Cell Structure
Once upon a time, the ‘Omics family had its granddaddy – GENOMICS – and then a smattering of lesser and much younger cousins, including: Proteomics, Metabolomics, Lipidomics, Transcriptomics,...
View ArticleClik here to view.
5 Key Challenges in Pesticide Screening – and How to Overcome Them.
Growing Use of Pesticides Pesticide use continues to rise, with the overall market for pesticides growing at anywhere from 3-8% a year. There’s variation in the various numbers found across the web,...
View ArticleClik here to view.
Bruker @ ASMS2014
ASMS kicks off down in Baltimore on Sunday, June 15, and hopefully you’ll be getting a chance to enjoy spectacular views of the Inner Harbor like this one: Bruker has tons of events, posters and oral...
View ArticleClik here to view.
Having an impact…II
At the annual ASMS conference down in Baltimore in mid-June, Bruker introduced the impact II – our follow-on to the industry changing impact QTOF platform. The impact II is our new ‘omics knowledge...
View ArticleClik here to view.
Mass Spec: Taking UHR (Ultra High Resolution) to a Whole New Level
Average cost to bring a drug to market: $5 Billion Average time to bring a drug to market: 9 Years These are truly staggering numbers – that’s $1.5+ million a day! But what’s that have to do with...
View ArticleClik here to view.
Improved workflows for Biopharmaceuticals characterization
Monoclonal antibody (mAb) Bruker is committed to build on key technologies such as Ultrahigh Resolution (UHR) QTOF and MALDI TOF/TOF to support the development of Biopharmaceuticals. The use of MALDI...
View Article
